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GENETIC DISORDERS – DEVELOPMENT
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Tubulointerstitial nephritis associated with a novel mitochon- chondrial DNA (mtDNA). Besides these oxidative phos-
drial point mutation. phorylation enzymes, mtDNA also encodes 22 tRNAs
Background. Nephropathy caused by mitochondrial disor- and 2 rRNAs. All of these 37 coding regions are tightlyders is a relatively newly recognized disease. Only a few cases
arranged in intronless mtDNA, which is 16,569 bp inhave been reported in the literature, and most of them are
humans [2].proximal tubulopathy-presenting Fanconi syndrome. Here we
report on a novel mutation in two familial cases of tubulointer- Ever since the first report of mtDNA mutation in
stitial nephropathy associated with concentrating defect. human disease in 1988, there has been a global increase
Methods. Renal biopsy specimens were examined by light in the reports of mitochondrial diseases [1]. So far, 109microscopy and electron microscopy. Mitochondrial genomic
pathogenic base substitution mutations have been identi-DNA isolated from renal biopsy specimens was amplified by
fied in the human mitochondrial genome [3]. Most ofpolymerase chain reaction (PCR) and sequenced in its entirety.
The DNA sequences were analyzed by (1) comparing with the the mitochondrial mutations do not have straightforward
Anderson et al’s mitochondrial sequences; (2) comparing with association with the clinical phenotypes. Therefore, a
DNA sequences obtained from 97 human controls, including given mutation may give rise to different clinical pres-both healthy individuals and patients with renal diseases; and
entation in different patients, namely clinical hetero-(3) comparing with the counterparts in 90 different species.
geneity. In contrast, a single clinical presentation mayResults. Dismorphic mitochondria with occasional intrami-
tochondrial inclusions were found in the renal tubular epithelial be caused by different mutations in different patients,
cells. A novel mitochondrial point mutation was identified at termed genetic heterogeneity. Because of heterogenei-
the position 608, that is, the distal end of the anticodon stem
ties on both the genetic and phenotypic aspects, manyof the tRNAPhe molecule. The A to G substitution at this posi-
researchers found difficulties in classifying mitochondri-tion was not observed in 97 human controls and was found to
be highly conserved in evolution. opathy. This issue is further complicated by the recent
Conclusions. We have identified an A608G mutation of mito- acquisition of a new clinical manifestation and novel
chondrial genome in two cases whose presentation include tubu- mtDNA mutations [4–8]. To add one more entity to
lointerstitial nephritis and stroke.
this growing list, here we report on an uncharacterized
phenotype of mitochondriopathy in two familial cases
associated with a novel point mutation in the coding
Mammalian cells utilize adenosine 59-triphosphate
region of tRNA for phenylalanine.
(ATP) for cellular function [1]. By oxidative phosphory-
lation, ATP is produced by aerobic metabolism of sugars Case report
and fats in the inner mitochondrial membrane. The oxi-
The reported cases were in one family. The parentsdative phosphorylation involves 83 different protein
were nonconsanguineous and healthy, and there aresubunits, among which 13 proteins are encoded by mito-
three children. The first child, a girl, died of herpetic
encephalitis at seven months of age. The mother denied
any prenatal illness at each pregnancy. She had neitherKey words: tRNAPhe mutation, stroke, renal tubular epithelial cells,
adenosine 59-triphosphate, DNA sequencing, genetics, A608G mutation. prenatal exposure to teratogenic drugs nor a family his-
tory of congenital diseases.Received for publication June 26, 2000
Patient 1, the second child of this family, was a boy,and in revised form September 7, 2000
Accepted for publication September 18, 2000 46 months of age, who presented in November 1998 to
another hospital with failure to thrive and chronic renalÓ 2001 by the International Society of Nephrology
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insufficiency. The patient was born after an uncompli- of 25%, a low tubular reabsorption of phosphate of 62%,
cated full-term pregnancy. Developmental delay was spot urine protein/creatinine ratio mildly elevated at 1.3,
noted in his infancy (not being capable of rolling over and unremarkable values of urinary calcium (1.9 mg/
until 10 months old and not being able to sit until 14 kg/24 hours) and urinary uric acid (uric acid 3 creatinine/
months of age). At the age one, he suffered from right UCr 5 0.47). In contrast to Fanconi syndrome, additional
side focal seizure, and the examination at a local hospital analysis of urine showed unremarkable amino acid val-
showed brain atrophy, anemia, and chronic renal insuf- ues other than mildly increased levels of hydroxyproline,
ficiency with blood urea nitrogen (BUN) and creatinine cytathionin, carnosine, and citruline. Biopsy specimens
elevated at 95 and 2.7 mg/dL, respectively. At the time of were taken from femoral muscle and kidney for further
this admission, pertinent physical examination findings studies. The patient was treated with sodium bicarbonate
included body weight 10 kg (,3rd percentile), height 84 for metabolic acidosis and calcium bicarbonate for renal
cm (,3rd percentile), head circumference 50 cm (at 50th osteodystrophy. After the biopsy diagnosis, additional
percentile), body temperature 37.38C, respiratory rate treatment was implemented (carnitine, Coenzyme Q10
20 per minute, blood pressure 79/54 mm Hg, regular and Vitamin complex). The overall condition improved
cardiac rate (120 per minute) with grade II systolic mur- somewhat with regular follow-up.
mur, mild dehydration, decreased limb muscle tone with
Patient 2, the third child of this family, was a 27-
atrophic appearance, and ataxia. There was no evidence
month-old boy born after an uncomplicated full-termof mental retardation and hepatosplenomegaly. Opthal-
pregnancy. The patient was brought to our clinic onemology studies showed no evidence of optic neuropathy.
month later for similar, but milder, manifestations, in-Radiographs revealed bone age being 1.5 to 2.0 years
cluding muscle weakness, ataxia, developmental delay,old. Cardiac ultrasound showed mild atrial septal defect.
and failure to thrive. After an episode of bronchiolitis,Nerve conduction velocity (NCV) and electromyogram
the patient showed athetotoid movement, restlessness,(EMG) showed features suggesting peripheral myopathy.
loss of speech and walking abilities, and dysphagia. Ad-Echocardiogram demonstrated paroxymal high voltage
mission EEG showed decreased background activity overslow wave of the left centroparietal area and excessive
the fronto-temporal area. Brain-computerized tomogra-b waves. Brain magnetic resonance imaging showed two
phy revealed an infarct in the lower part of the left basalsmall symmetrical lesions involving bilateral thalami
ganglia. The technetium99m hexamethyl propylene-near the internal capsule, one on each side. Initial labora-
amine oxime (Tc99m HMPAO) brain single photontory data revealed hemoglobin 7.9 g/dL, hematocrit
emission computed tomography (SPECT) revealed21.8%, white blood cells 8240/mm3, platelet 222,000/mm3,
mildly decreased uptake of radioactivity at the left sidemean corpuscular volume (MCV) 77.3 fL, mean cor-
puscular hemoglobin concentration (MCHC) 33.5%, fer- fronto-temporal and perital cortex, with mild decreased
ritin 47.7 ng/mL, vitamin B12 1101 pg/mL (normal 5 200 perfusion in the left basal ganglion. Laboratory data
to 950), folic acid 10.1 ng/mL (normal 5 3.0 to 17.0), included hemoglobin 7.5 g/dL, hematocrit 23.1%, BUN
and unremarkable serum levels of sodium, potassium, 48 mg/dL, creatinine 1.8 mg/dL, lactate 6.7 mg/dL, py-
calcium, chloride, aspartate aminotransferase (AST), al- ruvate 0.34 mg/dL, plasma-free carnitine 49.3 mmol/L,
anine aminotransferase (ALT), albumin, cholesterol, tri- and plasma total carnitine 78.2 mmol/L. Urine amino acid
glyceride, thyroid-stimulating hormone (TSH), FT4, and analysis showed elevated phosphoserine but decreased
prolactin. Further laboratory work-up showed BUN alanine, glutamine, histidine, and lysine levels. Renal
115 mg/dL, creatinine 2.4 mg/dL, estimated glomerular biopsy was performed for morphologic studies and DNA
filtration rate 17.3 mL/min/1.73 m2, uric acid 19.4 mg/dL, analysis.
ammonia 88 UG/dL, pyruvate 1.0 mg/dL (nl 5 0.3 to 0.6),
lactate 25.6 mg/dL (nl 5 5 to 19), plasma free carnitine
81.9 mmol/L (nl 5 34.3 to 53.1), and plasma total carni- METHODS
tine 127.8 mmol/L (nl 5 46.5 to 67.5). The urinary acidi- Pathology
fying capacity seemed preserved with urine pH being
Specimens from renal biopsy were divided into two5.5 at the time when plasma HCO23 was 17.7 mmol/L.
parts. The first was fixed in formalin for routine histology.Urinalysis revealed specific gravity 1.004 to 1.007, trace
The second was fixed with 2.5% glutaraldehyde for twoto 11 proteinuria, no glucosuria, and no cellular sedi-
hours, rinsed by 0.1 mol/L cacodylate buffer, fixed in 1%ments. Renal ultrasound showed bilaterally contracted
OsO4 for one hour, rinsed by 0.1 mol/L cacodylate buffer,kidneys with increased echogenicity and poor cortico-
and then dehydrated by alcohol before embedding inmedullary differentiation. Voiding cystourethrography
Spurr’s resin. The sectioned specimen was then stainedrevealed no evidence of vesicoureteral reflux. Renal tu-
by uranyl acetate and lead citrate for transmission elec-bular function test showed a high fractional excretion of
sodium of 7%, a high fractional excretion of potassium tron microscopy.
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Table 1. Location of the oligonucleotides used as primers for polymerase chain reaction
Sites of the PCR primersa
A:1st PCR
B:2nd PCR Forward primers Backward primers Product sizes (sitesa)
A1 534,553 1696,1677 1163 bp (534,1696)
A2 3007,3023 4508,4489 1502 bp (3007,4508)
A3 3952,3970 5917,5898 1966 bp (3952,5917)
A4 5720,5738 7608,7588 1889 bp (5720,7608)
A5 7392,7410 8628,8608 1237 bp (7392,8628)
A6 8282,8305 10107,10088 1826 bp (8282,10107)
A7 9911,9932 11873,11851 1963 bp (9911,11873)
A8 11711,11727 14208,14190 2498 bp (11711,14208)
A9 13914,13930 15865,15845 1952 bp (13914,15865)
A10 15553,15569 725,706 1769 bp (15553,725)
B1 571,598 1696,1677 1126 bp (571,1696)
B2 16193,16220 725,706 1129 bp (16193,725)
B3 1360,1380 2454,2435 1095 bp (1360,2454)
B4 2253,2272 3673,3654 1421 bp (2253,3673)
B5 3412,3430 4508,4489 1097 bp (3412,4508)
B6 3952,3970 5478,5459 1526 bp (3952,5478)
B7 5041,5062 5917,5898 877 bp (5041,5917)
B8 5720,5738 7220,7251 1551 bp (5720,7270)
B9 6381,6400 7608,7588 1226 bp (6381,7608)
B10 7392,7410 8372,8351 981 bp (7392,8372)
B11 8282,8305 9732,9713 1451 bp (8282,9732)
B12 9571,9590 10107,10088 537 bp (9571,10107)
B13 9911,9932 10955,10936 1045 bp (9911,10955)
B14 10834,10853 11873,11851 1040 bp (10834,11873)
B15 11711,11727 12780,12761 1070 bp (11711,12780)
B16 12385,12403 13930,13914 1546 bp (12385,13930)
B17 13914,13930 15050,15031 1137 bp (13914,15050)
B18 14913,14922 15569,15553 657 bp (14913,15569)
B19 15553,15569 45,26 1089 bp (15553,45)
a The sequences of primers correspond to the Anderson mitochondrial sequences [2]
DNA extraction, DNA primers, and DNA sequencing Reaction Kit and ABI Prism 377 Genetic Analyzer (PE
Applied Biosystems, Foster City, CA, USA).Total DNA from peripheral blood leukocytes was iso-
lated by using GFXe Genomic Blood DNA purification Polymerase chain reaction
kit (Amersham Pharmacia Biotech UK, Ltd., Little Chal-
The reaction was carried out in a DNA thermal cyclerfont, Buckinghamshire, UK). The extraction method was
(GeneAmp PCR System 9600; Perkin-Elmer, Fosterperformed according to the manufacturer’s instructions.
City, CA, USA). The reaction mixtures consisted ofTo isolate DNA from formalin-fixed, paraffin-embedded
0.5 mL of total cellular DNA, 100 pmol of each of therenal biopsies, five adjacent 8-mm sections were col-
oligonucleotide primers, 1 U of the Taq polymeraselected. The specimens were incubated in 300 mL xylene
(AmpliTaq Golde DNA polymerase; Perkin-Elmer Ce-
at 258C for five minutes, pelleted at 12,000 3 g for five tus, Norwalk, CT, USA), 200 mmol/L (each) deoxy-
minutes, resuspended in 300 mL of absolute alcohol at nucleotide triphosphate (Boehringer Mannheim, India-
room temperature, spun down, and then lyophilized. napolis, IN, USA), 1.5 mmol/L MgCl2, 5 mL of 10 3 PEThen the pellets were processed using Puregene DNA reaction buffer (500 mmol/L KCl, 150 mmol/L Tris-HCl,
isolation kit (Gentra, Minneapolis, MN, USA) according pH 8.0), and high-pressure liquid chromatography-grade
to manufacturer’s instruction, which includes proteinase distilled water to a total volume of 50 mL in a microcentri-
K (300 mg/mL) digestion overnight at 558C. The final fuge tube. The reaction protocol was as follows: (1) dena-
extracts were dissolved in TE buffer and kept in 48C for turation at 958C for 10 minutes; (2) amplification for 30
later use. cycles at 948C for 1 minute, 568C for 1 minute, and 728C
A total of 29 different oligonucleotide primers was used for 1 minute; and (3) extension at 728C for 10 minutes.
to amplify overlapping fragments of the entire mitochon-
drial genome by polymerase chain reaction (PCR; Table
RESULTS1). The sequences of primers were designed according to
Histologic findings and ultrastructural findingsthe Anderson et al mitochondrial sequences [2].
The PCR amplicons were sequenced using the ABI Renal biopsies for light microscopy showed ordinary
tubulointerstitial nephritis. The glomeruli contained small-PRISM BigDye Terminator Cycle Sequencing Ready
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Fig. 1. Histopathology of the renal biopsy.
The light microscopy (hematoxylin and eosin
stain, original magnification 3200) shows typi-
cal features of tubulointerstitial nephritis ex-
cept for the multinucleated giant cell (arrow),
which contains PAS-positive material.
sized sclerotic tufts and thickening of Bowman’s cap- Mitochondrial genomic DNA analysis of the renal
sules. Some Bowman’s capsules showed fibrosis on the biopsy tissue
internal surface. Many tubules contained amorphous ma- Mitochondrial DNAs were extracted from the paraf-
terial that was strongly positive for periodic acid-Schiff fin-embedded renal tissue of both cases. The whole mito-
(PAS). There was stripe-like tubular atrophy. The inter- chondrial genome was PCR amplified using 10 pairs of
stitium showed patchy fibrosis and focal chronic inflam- oligomers initially (Table 1). Fractionating the PCR
matory infiltrate. A multinucleated giant cell was identi- products on agarose gels did not show any visual differ-
fied in one of the patients (Fig. 1). This multinucleated ence in electrophoretic mobility between the amplicons
giant cell was characterized by peripherally located nu- and the calculated sizes, indicating the absence of major
clei and abundant pale cytoplasm, the latter of which deletion or insertion. Therefore, all PCR products and
contained PAS-positive materials with the appearance independent duplicates were sequenced on both strands.
of “flake” or “debris.” However, typical granulomas
Compared with the Anderson et al sequences [2] and
were not found at the place where this giant cell was
the available data [3], we identified five nondescribedlocated. This is an isolated finding with undetermined
nucleotide substitutes in the D-loop region and an A tosignificance. We do not know whether this giant cell is
G transition in position 608 (Fig. 3).directly related to mitochondriopathy.
Because PCR is known to introduce nucleotide substi-Electron microscopy revealed packed mitochondria of
tution during amplification, the entire mitochondrial ge-variable sizes and shapes in the renal tubular epithelial
nome was amplified again using a different set of PCRcells (Fig. 2). Some megamitochondria were irregular in
primers containing 19 pairs of oligomers (Table 1). Se-shape and contained crystalline inclusions that showed
quencing on both strands repeatedly showed identicalevenly spaced parallel lines; each was about 25 nm in di-
nucleotide substitutions at the same positions. In addi-ameter. Some mitochondria showed degeneration and
tion, the leukocyte mtDNAs of the patients also carriedwere characterized by disintegration of the internal archi-
the same mutation.tecture. Many mitochondria showed swollen intracristal
space accompanied by the compressed electron-dense
Significance of A608G transitionmatrix at the periphery. In contrast, others showed ex-
The nucleotide substitutions in the D-loop regionpanded chamber with electron-dense matrix in the center
are probably polymorphic in nature because DNA se-of the mitochondria, imparting a targetoid appearance.
quences in D loop are known to be variable enough forSome of these expanded matrix chambers were located
forensic application [9–12]. In contrast, A608G transitionat one end of the mitochondria, simulating a “tadpole”
is in the region that codes tRNA for phenylalanineshape.
(tRNAPhe). It is unique for the following reasons: First,Muscle biopsy did not show ragged-red fibers and dis-
morphic mitochondria. we examined the nucleotide at this position in 97 con-
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Fig. 2. Ultrastructure of disordered mitochondria (A). Electron micrographs of the distal tubular epithelium showing swollen mitochondria with
displayed bizarre configuration, some of which contain inclusions made up of stacked parallel cristae (38400). (B) The area pointed by an arrow
in the previous photo is examined under higher magnification (342,000) to show the details of the inclusions.
Fig. 3. DNA sequences in the coding region
of mitochondrial tRNAPhe. Sequence chroma-
togram of mitochondrial tRNAPhe region en-
compassing the A608G (lower panel: arrow
indicates an altered nucleotide “G”). Such a
nucleotide substitution has not been observed
in 97 controls (upper panel: the wild-type nu-
cleotide “A” appears in a selected control).
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trols, among which there were 24 healthy individuals and mutation at the tRNAPhe is G583A, which is located at
the distal end of the aminoacyl stem and causes mito-73 patients with biopsy-proven renal diseases. The results
showed that our patients had a G at position 608, while chondrial encephalomyopathy, lactic acidosis, and stroke-
like episodes (MELAS) [14]. Based on these observa-all 97 controls contained an A in this position (Fig. 3).
In addition, all reported data in the literature also tions, we believe that the A608G mutation is unique and
therefore pathogenic.showed an A at position 608 [3]. Therefore, A608G tran-
sition appears to be unique in humans. Second, we exam-
ined the DNA sequences of tRNAPhe among different
DISCUSSION
species. For this purpose, 90 species were randomly se-
The clinical presentation of our patients is similar tolected from GenBank and compared at the same posi-
MELAS, which is the most common mitochondrial dis-tion. The evolutionary comparison showed that 76 spe-
ease [15, 16]. However, other features of MELAS suchcies (,84%) had A, 9 species (10%) had T, 3 species
as sensorineural hearing loss and ragged-red fibers werehad C (,3%), and only 1 species had G (,1%) at this
not seen in our patients. Furthermore, the renal disorderposition (Fig. 4). Squid Loligo bleekeri is the only species
associated with MELAS is Fanconi syndrome, whereasthat has a G at this position [13]. Therefore, the A608G
our cases showed tubulointerstitial nephritis that re-transition appears to be significant from an evolutionary
sulted in a concentrating defect and chronic renal failure.point of view. Finally, we compared the secondary struc-
Accompanied by extrarenal symptoms, renal diseasesture of tRNAPhe molecules among these 90 species (Fig.
caused by mitochondrial disorders occur in three forms:4). As depicted in Figure 5, the human mitochondrial
glomerular nephropathy, proximal tubulopathy, and tu-tRNAPhe anticodon “GAA” sits within an anticodon loop
bulointerstitial nephropathy [17]. Glomerular diseasesmade up of seven mismatched nucleotides. Ten nucleo-
are presented by focal segmental glomerulosclerosis withtides flanking the anticodon loop anneal to form an anti-
nephrotic syndrome [18, 19]. The proximal tubulopathy,codon stem, which is composed of three paired bases on
the most common form of renal involvement, is usuallythe distal end, one paired base on the proximal end, and
presented with Fanconi syndrome [20]. The tubulointer-one unpaired base between them (3-1-1 pattern). The
stitial nephritis secondary to mitochondrial cytopathy is“A” at the position 608 is at the most distal end of the
rare, and only eight cases have been reported in theanticodon stem and is paired with a “T” at the position
literature thus far. Among them, two cases were associ-616. Thus, the A608G transition disrupted the A:T pair-
ated with 2.6,2.7 kb deletion in the mtDNA [21, 22],ing and gave rise to the following features: (1) The antico-
while three maternally related cases harbored a pointdon loop became nine nucleotides in length, and (2) the
mutation at the noncoding nucleotide [23]. However, itanticodon stem contained two pairs on the distal end,
is conceptually perplexing that a mutation of noncodingone pair on the proximal end, and one unpaired base
nucleotide can cause functional abnormalities. In con-between them (2-1-1 pattern). In other words, the
trast, our finding of a mutation in the coding regionA608G transition caused a shorting of the anticodon
appears to be biologically more significant, particularlystem and lengthening of the anticodon loop. An evolu-
with the evidence indicating that it is evolutionarily con-tionary comparison showed that 11 species had a nine-
served not only in human but also in other species (Fig.base long anticodon loop (Fig. 4). Among them, only
4). In addition, the mutation at the position 608 causesone had an anticodon stem with 2-1-1 pattern, simulating
structural changes of the anticodon stem and loop ofour patients. This species, that is, Pupa strigosa, however,
tRNA for phenylalanine.had a T at the position equivalent to human 608. The
The molecular mechanism of this mutation in mito-comparison of the tRNAPhe molecules also showed that
chondriopathy is unclear, but is probably due to the79 species (,88%) had a seven-base long anticodon loop,
alteration of the tertiary structure. It is known from thewhile 81 species (90%) had an anticodon stem containing
crystal structure of tRNA molecules that tRNA is anfour or five paired bases (Fig. 4). As to Loligo bleekeri
L-shaped molecule composed of a D loop and a TCCthat has a G at the same position, its anticodon stem
loop. Charging tRNAs with amino acids requires interac-contains four perfectly paired bases. Therefore, the
tion between tRNA with aminoacyl-tRNA synthetase.A608G in humans tRNAPhe appears to be unique from
The class I synthetase approaches the D-loop side of thestructural point of view.
tRNA, while the class II synthetase recognizes the TCCSo far, only three mutations of tRNA for phenylala-
loop. When tRNA interacts with synthetase of eithernine have been reported. Two mutations, that is, A606G
class, there is a tight contact between the anticodon stemand T618C, occur in anticodon stem of tRNAPhe [7, 8].
and the synthetase. This interaction causes distortion ofAlthough the nucleotides at these positions are not con-
the anticodon loop. Because A608G mutation involvesserved throughout different species (Fig. 4), the 606 and
both anticodon loop and stem, it is plausible that the618 mutations indeed cause myoglobinuria and mito-
chondrial myopathy, respectively. The third reported three-dimensional alteration can cause mitochondriopa-
Fig. 4. Evolutionary comparison of the anti-
codon loop and stem of the tRNA for phenyl-
alanine in 90 species. The list on the left con-
tains the probands and 90 species to be
compared. The species underlined have some
similarities to the probands. The DNA se-
quences following each species consist of an
anticodon loop (in the box) and an anticodon
stem (outside the box). The sequences on both
sides of the box are palindromic except the
shaded nucleotides.
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the exposure of aminoglycoside increases the penetrance
of deafness in the individuals harboring a homoplasmic
A1555G mutation [38]. It may also be exemplified by
increase the chance of clinical manifestation in LHON
patients following exposure to alcohol or tobacco [39].
All of these possibilities provide an explanation of why
she is a carrier.
Because cytopathy caused by mitochondrial abnor-
malities can only be morphologically recognized by elec-
tron microscopy, we recommend that unexplained dis-
eases involving multiple organs, especially those that
consume high energy, be subjected to ultrastructural ex-
amination. If dismorphic mitochondria are present,
mtDNA analysis should be performed. Size determina-
tion of defined mtDNA fragments may detect gross dele-
Fig. 5. Theoretical secondary structure of the mitochondrial tRNA for tion or insertion. However, subtle genetic alternationsphenylalamine with indicated mutations. Predicted two-dimensional
can only be assayed by sequencing the mitochondrialstructure of the tRNAPhe molecule with illustrated point mutations.
The base substitution at the position 608 is pointed by a filled arrow, genome in its entirety. Taking this approach, we may be
while the reported pathogenic point mutations (positions 583, 606, able to determine the genetic abnormalities of mitochon-618) are indicated by empty arrows.
driopathy, which is not an uncommon disease but is often
an overlooked entity.
thy. However, functional studies may be required to con- ACKNOWLEDGMENTS
firm its pathogenicity.
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